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Abstract
Autophagy is a central process in regulation of cell survival, cell death and proliferation and plays an important role in
carcinogenesis, including thyroid carcinoma. Genetic variation in autophagy components has been demonstrated to
influence the capacity to execute autophagy and is associated with disease susceptibility, progression and outcome. In the
present study, we assessed whether genetic variation in autophagy genes contributes to susceptibility to develop thyroid
carcinoma, disease progression and/or patient outcome. The results indicate that patients carrying the ATG5 single
nucleotide polymorphisms rs2245214 have a higher probability to develop thyroid carcinoma (OR 1.85 (95% CI 1.04–3.23),
P = 0.042). In contrast, no significant differences could be observed for the other genetic variants studied in terms of thyroid
carcinoma susceptibility. Furthermore, none of the selected genetic variants were associated with clinical parameters of
disease progression and outcome. In conclusion, genetic variation in ATG5, a central player in the autophagy process, is
found to be associated with increased susceptibility for thyroid carcinoma, indicating a role for autophagy in thyroid
carcinogenesis.
Citation: Plantinga TS, van de Vosse E, Huijbers A, Netea MG, Joosten LAB, et al. (2014) Role of Genetic Variants of Autophagy Genes in Susceptibility for Non-
Medullary Thyroid Cancer and Patients Outcome. PLoS ONE 9(4): e94086. doi:10.1371/journal.pone.0094086
Editor: David L. Boone, University of Chicago, United States of America
Received December 13, 2013; Accepted March 10, 2014; Published April 16, 2014
Copyright:  2014 Plantinga et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: TSP was supported by a Veni grant of the Netherlands Organization for Scientific Research (NWO). MGN was supported by a Vici grant of the
Netherlands Organization for Scientific Research (NWO). The funders had no role in study design, data collection and analysis, decision to publish, or preparation
of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: Romana.Netea-Maier@radboudumc.nl
Introduction
Epithelial cell derived non-medullary thyroid cancer (NMTC) is
the most common endocrine malignancy with a rising incidence
during the last decades of which papillary thyroid carcinoma
(PTC) and follicular thyroid carcinoma (FTC) represent the vast
majority of cases [1–3]. Although some tumor-initiating events
and susceptibility factors have been identified (radiation exposure,
several genetic factors such as genetic rearrarangements or
mutations in RET, PTEN and APC) [4], the pathogenesis of
NMTC is not completely understood. A better understanding of
the underlying molecular mechanisms involved in the develop-
ment of NMTC could provide diagnostic and prognostic tools and
could be a potential source of novel molecular targets for therapy.
Increasing evidence suggests that autophagy plays an important
role in the pathophysiology of the malignant process. Autophagy is
a complex process of auto-digestion in conditions of cellular stress,
hypoxia or energy deprivation. Upon activation, an autophago-
some is formed which engulfs cellular components such as
organelles, ribosomes and protein aggregates, which are subse-
quently degraded by fusion of the autophagosome with a
lysosome. These degradation products can be reused for building
macromolecules and for cellular energy metabolism [5–7]. In
addition, autophagy has an important role in the regulation of cell
death, cell differentiation, induction of cell cycle arrest, and
modulation of inflammation [8]. Autophagy may have both
preventive and promotional effects on tumorigenesis, which is
probably dependent on the type of autophagy initiation, tumor cell
type and the stage of tumor development [9,10]. Hence, it is
important to identify the mechanisms that regulate autophagy in
malignant transformed cells.
Essential components of the autophagy process are the
evolutionary highly conserved ATG proteins, of which more than
30 have currently been identified in yeasts [11,12]. Common
germline genetic variants within genes coding for autophagy
components were recently demonstrated to be associated with
human disease, ranging from inflammatory bowel disease [13–15]
to neurodegeneration [16], infectious diseases [17,18] and allergy
[19]. However, despite its central role in cancer initiation and
progression, the role of common germline genetic variation within
the autophagy system for cancer susceptibility, in particular
NMTC, is largely unexplored. Recently, we described that a
genetic variant in the autophagy gene ATG16L1 has an important
impact on susceptibility to NMTC [20]. In the present study we
broadened the aim of our investigation to assess the potential
association of a much broader range of genetic variants in
autophagy genes with susceptibility for NMTC, progression and
outcome.
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Materials and Methods
Ethics statement
The study was approved by the Ethical Committee of Radboud
University Medical Centre, Nijmegen, The Netherlands. All
subjects gave written informed consent. The study has been
performed in accordance with the Declaration of Helsinki.
Thyroid carcinoma patients
All patients with histologically confirmed non-medullary
epithelial cell derived NMTC who visited the outpatient clinic at
the Division of Endocrinology of the Department of Internal
Medicine, Radboud University Medical Centre, Nijmegen, The
Netherlands, were asked to participate in genetic testing. The
recruitment of the patients took place between November 2009
and June 2010. Primary treatment of the patients consisted of total
or near-total thyroidectomy in all of the patients, and modified
radical lymph node dissections in patients with confirmed nodal
metastases. This was followed by ablation with radioactive iodine
(I131, RAI) of residual thyroid tissue 4–6 weeks after surgery. If
necessary, patients were treated multiple times with RAI to reach
remission. Initial cure was defined as undetectable Thyroid
Stimulating Hormone stimulated thyroglobulin (Tg) in the absence
of anti-Tg antibodies and no evidence of loco-regional disease or
distant metastasis on whole body iodine scans (WBS) and/or neck
ultrasonography examinations at six to nine months after RAI
ablation. Tumor recurrence was defined as new evidence of loco-
regional disease or distant metastasis after successful primary
therapy. Current disease status was defined as ‘‘in remission’’ in
case of undetectable Tg in the absence of anti-Tg antibodies and
no evidence of loco-regional disease or distant metastases at the
last follow-up visit. Persistent disease status was defined as
detectable Tg and/or evidence of loco-regional disease or distant
metastases.
Demographic and clinical characteristics (tumor histology and
TNM staging), treatment (number of RAI therapy sessions,
cumulative RAI dose), follow-up time, the number of re-operations
and external beam radiation therapy, if applicable, were retrieved
from the patient’s medical records (Table 1). The Dutch
population based control group consisted of 189 healthy controls
(48% women, mean age 61610 (SD) years) having no evidence of
thyroid cancer or other malignancies.
Genotyping
Venous blood was drawn from the cubital vein of all
participants into 10 ml EDTA tubes (Monoject). DNA was
isolated from whole blood by using the isolation kit Puregene
(Gentra Sytems, MN, USA), according to the manufacturer’s
protocol. Coding non-synonymous single nucleotide polymor-
phisms (SNPs) and a few SNPs in untranslated regions of the
analyzed genes were selected based on previously published
associations with human diseases and/or known functional effects
on protein function or gene expression. A total of 10 SNPs in
ATG2B, ATG5, ATG10, IRGM, LAMP1, LAMP3 and WIPI1 were
Table 1. Clinical, pathological and treatment characteristics of the thyroid carcinoma patient cohort.
Variable Total (±SD) Variable Total (%)
Patients (number) 139 Cum. RAI dose #3.7 GBq 35 (25.2%)
Gender (Female/Male) 104/35 Cum. RAI dose 3.8–7.4 GBq 50 (36.0%)
Age at diagnosis, years (mean 6 SD) 38.9 (612.8) Cum. RAI dose .7.4 54 (38.8%)
Tumor histology Total (±SD) TNM staging Total (%)
Papillary thyroid cancer 99 T1 41 (29.5%)
Follicular thyroid cancer 33 T2 45 (32.3%)
Both papillary and follicular 5 T3 23 (16.5%)
Differentiated thyroid cancer, not further specified 1 T4 11 (8.0%)
Poorly differentiated thyroid cancer 1 Tx 19 (13.7%)
Re-operations 9 N0 72 (51.8%)
External beam radiation therapy 2 N1 46 (33.1%)
Mean duration follow-up, months (mean 6 SD)` 128 (6112) Nx 21 (15.1%)
RAI sessions 0–1 82 (59.0%) M0 96 (69.1%)
RAI sessions $2 57 (41.0%) M1 3 (2.1%)
Persistent after ablation 60 (43.2%) Mx 40 (28.8%)
`since diagnosis of NMTC (primary surgery).
doi:10.1371/journal.pone.0094086.t001
Table 2. Genotyped SNPs in genes encoding components of
the autophagy machinery.
Gene SNP ID Gene region Amino acid change
ATG2B rs9323945 Exon 19 Asn1124Asp
rs3759601 Exon 25 Gln1383Glu
ATG5 rs2245214 Intron 6 -
ATG10 rs3734114 Exon 1 Ser62Pro
rs1864183 Exon 4 Thr212Met
IRGM rs72553867 Exon 1 Thr94Lys
rs4958847 39 UTR -
LAMP1 rs9577229 Exon 3 Ala204Val
LAMP3 rs482912 Exon 2 Ile318Val
WIPI1 rs883541 Exon 1 Thr31Ile
UTR= untranslated region.
doi:10.1371/journal.pone.0094086.t002
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genotyped (Table 2) with the use of a mass-spectrometry
genotyping platform. All SNPs are in Hardy-Weinberg equilibri-
um in both patient and control groups. Quality control was
performed by duplicating samples within and across plates and by
the incorporation of positive and negative control samples.
Statistical analysis
The difference in genotype frequencies between the patients
and the control group were analyzed in a dominant, gene dosage
and recessive model using logistic regression. The effect of the
genotypes on epithelial derived NMTC susceptibility was estimat-
ed by calculating odds ratios (ORs) and their 95% confidence
intervals (95% CI) using the same statistical methods. We also
performed x2 analysis, and if applicable logistic regression, to
determine whether tumor size, cumulative RAI dose, number of
RAI treatments, disease status after thyroidectomy plus radio-
ablation (if applicable) and current disease status were associated
with the genotype of the analyzed autophagy genes. The following
parameters were analyzed: 1) the tumor size at time of diagnosis
was classified according to the 6th edition of the UICC TNM
classification [21]; 2) the number of RAI treatments (including
RAI ablation) as 0–1 treatments (e.g. no RAI ablation or
exclusively ablation of thyroid remnants after (near) total
thyroidectomy) or $2 treatments; 3) the cumulative RAI dosage
as 0–3.7 GBq (0–100 mCi), 3.8–7.4 GBq (101–200 mCi) or
.7.4 GBq (.200 mCi); 4) the disease status after ablation as
remission or persistent and 5) the current disease status as
remission, persistent or recurrent (after previously documented
remission).
To test for differences between the three different genotype
groups (homozygous wild-type (ancient), heterozygous, homozy-
gous variant (derived)) in mean age at diagnosis, sex distribution or
tumor histology (potential confounders), one-way ANOVA and
Pearson x2 analysis were used when appropriate. All statistical
analyses were carried out with the SPSS software package (version
20.0). Overall, statistical tests were two-sided and a p-value below
0.05 was considered statistically significant.
Table 3. Genetic distribution of genetic variants in autophagy genes in a cohort of thyroid carcinoma patients (N= 139) and
healthy controls (N = 189).
Gene Polymorphism Allelic distribution OR (95% CI)* P-value*
ATG2B rs9323945 CC TC 0.65 (0.20–2.18) 0.547
Asn1124Asp Patients 133 (96%) 6 (4%)
Controls 184 (97%) 5 (3%)
rs3759601 CC GC GG 0.70 (0.44–1.11) 0.125
Gln1383Glu Patients 50 (36%) 67 (48%) 22 (16%)
Controls 54 (29%) 105 (55%) 30 (16%)
ATG5 rs2245214 CC CG GG 1.85 (1.04–3.23) 0.042
Intron 6 Patients 41 (30%) 67 (48%) 31 (22%)
Controls 66 (35%) 98 (52%) 25 (13%)
ATG10 rs3734114 CC TC TT 1.53 (0.98–2.37) 0.060
Ser62Pro Patients 9 (6%) 40 (29%) 90 (65%)
Controls 12 (6%) 74 (39%) 103 (55%)
rs1864183 AA GA GG 1.41 (0.85–2.33) 0.204
Thr212Met Patients 32 (23%) 68 (49%) 39 (28%)
Controls 46 (24%) 102 (54%) 41 (22%)
IRGM rs72553867 CC CA 1.59 (0.76–3.33) 0.256
Thr94Lys Patients 124 (89%) 15 (11%)
Controls 175 (93%) 14 (7%)
rs4958847 AA GA GG 0.88 (0.54–1.43) 0.620
39 UTR Patients 1 (1%) 36 (26%) 102 (73%)
Controls 3 (2%) 44 (23%) 142 (75%)
LAMP1 rs9577229 CC TC 0.79 (0.05–12.78) 1.000
Ala204Val Patients 138 (99%) 1 (1%)
Controls 188 (99%) 1 (1%)
LAMP3 rs482912 AA GA GG 0.78 (0.51–1.20) 0.276
Ile318Val Patients 11 (8%) 63 (45%) 65 (47%)
Controls 18 (10%) 70 (37%) 101 (53%)
WIPI1 rs883541 AA GA GG 1.35 (0.88–2.08) 0.185
Thr31Ile Patients 74 (53%) 58 (42%) 7 (5%)
Controls 115 (61%) 66 (35%) 8 (4%)
* Dominant model.
doi:10.1371/journal.pone.0094086.t003
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Results
Genetic susceptibility analysis
From all the patients with NMTC who visited the outpatient
clinic of the Radboud University Medical Centre, Nijmegen, The
Netherlands between November 2009 and June 2010, 139 patients
(104 women; mean age 38.9612.8 (SD) years at time of blood
sampling) agreed to participate in the study. The clinical and
demographical characteristics of the NMTC patients are summa-
rized in Table 1. No statistically significant differences were found
between the patients with different autophagy genetic variant
genotypes with respect to the mean age at diagnosis, gender or
tumor histology (data not shown).
Statistical analysis of autophagy genetic variants for NMTC
susceptibility revealed a statistically significant assocation with the
ATG5 rs2245214 single nucleotide polymorphism. Analysis by
applying a dominant model showed an increased risk of the CG/
GG genotype for the diagnosis of NMTC compared to the CC
genotype (OR=1.85, P = 0.042), whereas no statistical signifi-
cance was reached with either a recessive model or a gene dosage
model (data not shown). For the other autophagy genetic variants
studied, no statistically significant differences were observed
concerning susceptibility to develop NMTC with any of the
association models tested, i.e. recessive, gene dosage and dominant
models (Table 3 and data not shown).
Genotype - phenotype associations
Within the NMTC patient cohort, associations between
genotype and tumor size (T stage), number of I131 treatments,
cumulative I131 dose, disease status after ablation and current
disease status were assessed using Pearson x2 analysis. For the
ATG5 rs2245214 single nucleotide polymorphism the results are
depicted in Table 4. There were no statistically significant
differences between the patients in the different genotype groups
with respect to TNM staging, number of RAI treatments,
cumulative RAI dose and current disease status (Table 4).
Furthermore, no associations were observed for any of the other
investigated autophagy genetic variants with these clinical
parameters (data not shown).
Discussion
The present study was performed to investigate whether
common genetic variants in human autophagy genes are
associated with NMTC susceptibility, severity and/or clinical
outcome. We found that one of the selected genetic variants, the
ATG5 rs2245214 single nucleotide polymorphism, is significantly
associated with NMTC susceptibility, but not with NMTC severity
or outcome. Furthermore, none of the other selected autophagy
SNPs were associated with either susceptibility for NMTC,
severity of the disease or clinical outcome.
All of the investigated proteins are involved in the autophagy
machinery, some in the early phase of autophagosome formation
(ATG2B, ATG5, ATG10, IRGM and WIPI1), the others in the
late phase of autophagosome-lysosome fusion (LAMP1 and
LAMP3) [22,23]. In the process of autophagosome formation,
ATG5 is recruited to take part in a large protein complex together
with ATG12 and ATG16L1 to assemble the double membrane
surrounding the autophagic cargo [24,25]. Autophagy is active at
basal levels in all cell types, where it is believed to play a
housekeeping role in recycling intracellular components.
In terms of carcinogenesis, the role of autophagy is complex and
depends on the type of cancer and the stage of the disease. Defects
in autophagy may mediate carcinogenesis through accumulation
of protein aggregates and damaged organelles. On the other hand,
in apoptotic-competent cells autophagy is cytoprotective, as these
cells depend on autophagy to cover their increased energy
expenditure [9]. Despite the important role of autophagy for the
pathogenesis of cancer, surprisingly little is known about the
genetic variation in autophagy genes and its influence on
carcinogenesis. In the present study, we assessed the effect of a
broad range of genetic variants in autophagy genes for suscepti-
bility to and treatment outcome of differentiated epithelial cell
derived NMTC.
The present genetic association study revealed that the G allele
of the ATG5 rs2245214 SNP is associated with increased
susceptibility for developing NMTC. In contrast, this ATG5 SNP
was not associated with NMTC severity and outcome as reflected
by TNM staging, cumulative RAI dose and disease persistence.
The fact that the genetic variants in the other selected autophagy
genes are not associated with NMTC susceptibility and severity in
our cohort of NMTC patients could indicate that either these
proteins have no prominent role in NMTC carcinogenesis or the
consequences of the genetic variants for the function of the
Table 4. Summary of ATG5 rs2245214 genotype in relation to
NMTC phenotype association parameters within the NMTC
patient group (N= 139).
Variable CC (%) CG (%) GG (%) Total P-value`
T stage 0.962
T1 13 (31%) 18 (27%) 10 (32%) 41
T2 12 (29%) 22 (33%) 11 (35%) 45
T3 6 (15%) 13 (19%) 4 (13%) 23
T4 4 (10%) 5 (8%) 2 (7%) 11
Tx 6 (15%) 9 (13%) 4 (13%) 19
N stage 0.176
N0 23 (56%) 33 (49%) 16 (52%) 72
N1 9 (22%) 27 (40%) 10 (32%) 46
Nx 9 (22%) 7 (11%) 5 (16%) 21
M stage 0.633
M0 26 (64%) 49 (73%) 21 (68%) 96
M1 1 (2%) 2 (3%) 0 3
Mx 14 (34%) 16 (24%) 10 (32%) 40
RAI treatments (n)* 0.856
0–1 24 (59%) 39 (58%) 19 (61%) 82
$2 17 (41%) 28 (42%) 12 (39%) 57
Cumulative RAI dose (GBq) 0.626
#3.7 8 (20%) 17 (25%) 10 (32%) 35
3.8–7.4 17 (41%) 22 (33%) 11 (36%) 50
.7.4 16 (39%) 28 (42%) 10 (32%) 54
Disease after ablation 0.872
Remission 25 (61%) 37 (55%) 17 (55%) 79
Persistent 16 (39%) 30 (45%) 14 (45%) 60
Current disease 0.230
Remission 32 (78%) 48 (72%) 27 (87%) 107
Persistent 7 (17%) 18 (27%) 3 (10%) 28
Recurrent 2 (5%) 1 (1%) 1 (3%) 4
*Including radio-ablation.
`Calculated by Pearson x2 analysis.
doi:10.1371/journal.pone.0094086.t004
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respective proteins is relatively limited. However, replication
studies in other NMTC cohorts should be performed to firmly
demonstrate the lack of association of these genetic variants with
NMTC susceptibility and severity.
Genetic variation in ATG5 has previously been linked to
systemic lupus erythematosus (same SNP) [26,27], asthma [19]
and neurodegenerative disease [28], indicating the important role
of ATG5 in human health and disease. However, the conse-
quences of these genetic variants of ATG5 for the function of the
protein are still unknown and warrant further investigation that
should also include previously reported non-autophagic functions
of ATG5 [29,30].
Our previous report of the genetic association of the ATG16L1
T300A polymorphism (rs2241880) with NMTC susceptibility and
severity [20] is now extended by the demonstrated association of
the ATG5 rs2245214 polymorphism with NMTC susceptibility in
the present study, confirming the role of autophagy in NMTC
pathogenesis. Of note, no additive effects of the two SNPs in ATG5
and ATG16L1 were observed, indicating that the two SNPs act
independently. Interestingly, both the role of autophagy in NMTC
and the therapeutic potential of targeting autophagy for NMTC
treatment are confirmed by other studies [10,31–33].
Multiple studies have shown the important role of autophagy in
NMTC pathogenesis, representing one of the most prominent
downstream pathways of the often aberrantly regulated RAS/
RAF/MEK/ERK and PI3K/Akt/mTOR pathways in NMTC,
leading to inactivation of the autophagy machinery [34,35]. In line
with these studies, reactivation of autophagy by inhibition of the
mTOR kinase results in resensitization of NMTC to chemo- and
radiotherapy [33]. In contrast, also opposite effects of signalling
through these oncogenes has been described that activate basal
autophagy, indicating the complex and context-dependent effects
of these pathways on autophagy [36–38]. Genetic variants of
autophagy genes leading to either less or more functional
autophagy machinery could subsequently result in abolished
therapy sensitivity and increased carcinogenesis, providing a
potential mechanism underlying the observed genetic associations.
Additional studies are warranted to dissect the role of autophagy in
either promoting or inhibiting carcinogenesis and therapy
sensitivity in the context of NMTC subtypes to identify the most
effective targeted therapies.
An important point to be considered is that of correction for
multiple testing in this study. It has to be taken into account that,
when applying correction for multiple testing, statistical signifi-
cance of the ATG5 rs2245214 SNP association with NMTC
susceptibility is lost. Another limitation that has to be taken into
account is the missing data points for the clinical assessment of
TNM stageing, which has decreased the statistical power to
demonstrate significant differences. The findings obtained in the
present study therefore need to be confirmed in larger prospective
cohorts in order to draw firm conclusions regarding the definitive
role of the genetic polymorphisms described here. Despite of this,
it is nevertheless important to observe that the earlier association
between ATG16L1 and NMTC provides indirect support for the
findings of the present study.
In conclusion, we have identified the ATG5 rs2245214 genetic
variant as a genetic susceptibility factor in thyroid carcinogenesis.
These findings emphasize the therapeutic potential of modulation
of ATG5 and ATG16L1, most probably as part of the autophagy
machinery, as a novel treatment strategy for NMTC patients.
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